Pharmacoeconomic properties of disease-modifying antirheumatic drugs

[1]  Michael Drummond,et al.  How to use an Article on Economic Analysis of Clinical Practice , 2005 .

[2]  Linda C. Li,et al.  The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study , 2004, Annals of the rheumatic diseases.

[3]  M. Brown,et al.  GAIN OF FUNCTION ANKH VARIANTS CAUSE BOTH FAMILIAL AND SPORADIC CALCIUM PYROPHOSPHATE DIHYDRATE CHONDROCALCINOSIS , 2004 .

[4]  A. Brennan,et al.  Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. , 2004, Rheumatology.

[5]  Peter A Ubel,et al.  What is the price of life and why doesn't it increase at the rate of inflation? , 2003, Archives of internal medicine.

[6]  M. Boers.  Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard? , 2003, Arthritis and rheumatism.

[7]  T. Pincus,et al.  Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission. , 2003, The Journal of rheumatology.

[8]  M. Drummond,et al.  Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. , 2003, The Journal of rheumatology.

[9]  M. Drummond,et al.  OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. , 2003, The Journal of rheumatology.

[10]  L. Jönsson,et al.  The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. , 2003, Rheumatology.

[11]  P. Tugwell,et al.  Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[12]  J. Wong,et al.  Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. , 2002, The American journal of medicine.

[13]  Hyon K. Choi,et al.  A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. , 2002, The Journal of rheumatology.

[14]  C. Gordon,et al.  Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group. , 2000, The Journal of rheumatology.

[15]  K. Kuntz,et al.  A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[16]  H. Paulus,et al.  Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. , 2000, The Journal of rheumatology.

[17]  S. Hill,et al.  Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. , 2000, JAMA.

[18]  David Canning,et al.  The Health and Wealth of Nations , 2000, Science.

[19]  N. Cooper.  Economic burden of rheumatoid arthritis: a systematic review. , 2000, Rheumatology.

[20]  E. Yelin,et al.  An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. , 1999, Arthritis and rheumatism.

[21]  A. Detsky,et al.  Guidelines for measuring the costs and consequences of adopting new pharmaceutical products: are they on track? , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  M F Drummond,et al.  Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. , 1997, JAMA.

[23]  M F Drummond,et al.  Users' Guides to the Medical Literature: XIII. How to Use an Article on Economic Analysis of Clinical Practice A. Are the Results of the Study Valid? , 1997 .

[24]  A S Detsky,et al.  Primer on Medical Decision Analysis: Part 2—Building a Tree , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  A S Detsky,et al.  Primer on Medical Decision Analysis: Part 1—Getting Started , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[26]  A S Detsky,et al.  Primer on Medical Decision Analysis: Part 5—Working with Markov Processes , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  A S Detsky,et al.  Primer on Medical Decision Analysis: Part 3—Estimating Probabilities and Utilities , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[28]  A S Detsky,et al.  Primer on Medical Decision Analysis: Part 4-Analyzing the Model and Interpreting the Results , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[29]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[30]  van der Heijde Dm,et al.  Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993 .

[31]  G. Guyatt,et al.  Users' guides to the medical literature. , 1993, JAMA.

[32]  M A Koopmanschap,et al.  Towards a new approach for estimating indirect costs of disease. , 1992, Social science & medicine.

[33]  A S Detsky,et al.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[34]  H. Holman,et al.  Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.